Autolus chief medical officer (CMO) Vijay Peddareddigari is leaving the corporate to return to the U.S. The British CAR-T biotech disclosed the departure alongside information that Nushmia Khokhar, who crossed paths with Peddareddigari at Johnson & Johnson, has stepped as much as a medical SVP place.
Peddareddigari joined Autolus as CMO in 2016. The timing of Peddareddigari’s arrival meant his spell at Autolus lined the interval wherein the biotech constructed out its clinical-phase pipeline, which now options 4 CAR-T cell therapies towards targets together with CD19, CD19xCD22, TRBC1 and GD2. The cell therapies function applied sciences designed to supply extra management over security and efficacy.
In an announcement, CEO Christian Itin stated Peddareddigari “performed a key management position in establishing and executing the medical growth technique” for Autolus’ cell therapies.
Having guided Autolus by way of its early strikes into the clinic, Peddareddigari is now leaving the corporate and returning to the U.S. Peddareddigari labored at MD Anderson Most cancers Middle earlier than taking over posts at websites run by GlaxoSmithKline and J&J within the Philadelphia space.
The departure of Peddareddigari comes concurrently the promotion of Khokhar to go of medical growth. Khokhar, like Peddareddigari, joined Autolus from J&J, the place she was world medical chief for daratumumab, the anti-CD38 blockbuster offered as Darzalex. Itin stated Khokhar “has been instrumental in overseeing the event of our medical packages” since becoming a member of in 2017.
Autolus disclosed the modifications to its medical growth group in an announcement that additionally revealed the appointment of Jay Backstrom to its board of administrators. Backstrom has headed up R&D at Acceleron Pharma since late final 12 months. Previous to that, Backstrom spent round a decade at Celgene, the place he rose to the rank of CMO.